SCIENTIFIC INDUSTRIES INC 10-Q

10-Q 1 a12312010q.htm 10-Q a12312010q       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-Q       ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the quarterly period ended December 31, 2020     ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to________   Commission file number 0-6658   SCIENTIFIC INDUSTRIES, INC. (Exact Name of Registrant in Its Charter)     Delaware 04-2217279 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)     80 Orville Drive, Suite 102, Bohemia, New York 11716 (Address of principal executive offices) (Zip Code)     (631) 567-4700 (Registrant’s telephone number, including area code)   Not Applicable (Former name, former address and former fiscal year, if changed since last report)     Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No   Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ No   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.   Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ (Do not check if a smaller reporting company) Smaller reporting company ☒   Emerging Growth ☐   Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) Yes ☐ No ☒   The number of shares outstanding of the registrant’s common stock, par value $.05 per share (“Common Stock”) as of February 8, 2021 is 2,861,263 shares.                 SCIENTIFIC INDUSTRIES, INC.   Table of Contents         PART I - Financial Information         Item 1 . CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)           Condensed Consolidated Balance Sheets 2         Condensed Consolidated Statements of Operations 3         Condensed Consolidated Statements of Changes in Shareholders’ Equity 4         Condensed Consolidated Statements of Cash Flows 5         Notes to Unaudited Condensed Consolidated Financial Statements 6       Item 2 . MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 15       Item 4. CONTROLS AND PROCEDURES 17       PART II - Other Information             Item 6. EXHIBITS AND REPORTS ON FORM 8-K 17       S IGNATURE   18               PART I – FINANCIAL INFORMATION Item 1. Financial Statements SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS   ASSETS       December 31, 2020     June 30, 2020   Current assets:   (Unaudited)         Cash and cash equivalents   $ 1,111,300     $ 7,559,700   Investment securities     5,784,800       331,800   Trade accounts receivable, less allowance for doubtful accounts of $11,600 at December 31, 2020 and June 30, 2020     1,554,500       1,064,000   Inventories     2,639,200       2,541,000   Income tax receivable     333,600       334,800   Prepaid expenses and other current assets     316,000       112,400   Assets of discontinued operations     -       793,000   Total current assets     11,739,400       12,736,700                     Property and equipment, net     310,700       278,300                     Intangible assets, net     128,100       128,700                     Goodwill     257,300       257,300                     Other assets     57,900       56,000                     Deferred taxes     811,100       537,100                     Operating lease right-of-use assets     765,100       803,300                     Total assets   $ 14,069,600     $ 14,797,400     LIABILITIES AND SHAREHOLDERS’ EQUITY   Current liabilities:             Accounts payable   $ 584,000     $ 334,600   Accrued expenses and taxes     378,400       679,000       Contract liabilities     -       20,000   Contingent consideration, current portion     97,600       111,000   Bank overdraft     225,000       43,100   Liabilities of discontinued operations     151,500       240,900   Operating lease liabilities, current portion     128,000       195,800   Payroll Protection Program loan     563,800       563,800   Total current liabilities     2,128,300       2,188,200                     Contingent consideration payable, less current portion     247,000       247,000   Operating lease liabilities, less current portion     711,300       640,800                     Total liabilities     3,086,600       3,076,000   Shareholders’ equity:                 Common stock, $.05 par value; 7,000,000 shares authorized; 2,881,065 shares issued; 2,861,263 shares outstanding at December 31, 2020 and June 30, 2020     144,100       144,100          Additional paid-in capital     8,745,700       8,608,300          Retained earnings     2,145,600       3,021,400         11,035,400       11,773,800   Less common stock held in treasury at cost, 19,802 shares     52,400       52,400                     Total shareholders’ equity     10,983,000       11,721,400                     Total liabilities and shareholders’ equity   $ 14,069,600     $ 14,797,400     2       SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)       For the Three Month Period Ended December 31,     For the Three Month Period Ended December 31,     For the Six Month Period Ended December 31,     For the Six Month Period Ended December 31,       2020     2019     2020     2019                             Revenues   $ 2,717,400     $ 2,232,800     $ 4,736,500     $ 4,098,300                                     Cost of revenues     1,311,300       1,052,500       2,273,700       1,942,000                                     Gross profit     1,406,100       1,180,300       2,462,800       2,156,300                                     Operating expenses:                                 General and administrative     536,900       478,400       1,056,100       948,400   Selling     778,900       280,600       1,272,800       535,400   Research and development     329,700       260,000       574,000       496,400                                     Total operating expenses     1,645,500       1,019,000       2,902,900       1,980,200                                     Income (loss) from operations     (239,400 )     161,300       (440,100 )     176,100                                         Other income:                                     Other income, net     18,200       2,900       16,200       2,200       Interest income     35,300       9,200       48,900       9,700   Total other income, net     53,500       12,100       65,100       11,900                                     Income (loss) before income tax expense (benefit)     (185,900 )     173,400       (375,000 )     188,000                                     Income tax expense (benefit):                                 Current     -       -       -       -   Deferred     (47,600 )     34,100       (94,100 )     52,000                                     Total income tax expense (benefit) from continuing operations     (47,600 )     34,100       (94,100 )     52,000                                     Net income (loss) from continuing operations     (138,300 )     139,300       (280,900 )     136,000                                     Discontinued operations (Note 9):                                                                        Loss from discontinued operations (including loss on      disposal of $405,400), in 2020 periods     (639,500 )     (170,400 )     (774,800 )     (260,700 )        Income tax benefit, deferred     (165,300 )     (34,700 )     (179,900 )     (72,100 )                                        Net loss from discontinued operations     (474,200 )     (135,700 )     (594,900 )     (188,600 )                                   Net income (loss)   $ (612,500 )   $ 3,600     $ (875,800 )   $ (52,600 )                                   Basic and diluted (loss) per common share                                                                   Continuing operations   $ (.05 )   $ .09     $ (.10 )   $ .09                                     Discontinued operations   $ (.17 )   $ (.09 )   $ (.21 )   $ (.13 )                                   Consolidated operations   $ (.22 )   $ .00     $ (.31 )   $ (.04 )                                                                     See notes to unaudited condensed consolidated financial statements.     3         SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED)             Additional                 Total       Common Stock     Paid-in     Retained     Treasury Stock     Shareholders’   Fiscal Year 2021:   Shares     Amount     Capital     Earnings     Shares     Amount     Equity                                               Balance, July 1, 2020     2,881,065     $ 144,100     $ 8,608,300     $ 3,021,400       19,802     $ 52,400     $ 11,721,400                                                             Net loss     -       -       -       (263,300 )     -       -       (263,300 )                                                           Stock-based compensation     -       -       61,300       -       -       -       61,300                                                             Balance, September 30, 2020     2,881,065       144,100       8,669,600       2,758,100       19,802       52,400       11,519,400                                                             Net loss     -       -       -       (612,500 )     -       -       (612,500 )                                                           Stock-based compensation     -       -       76,100       -       -       -       76,100                                                             Balance, December 31, 2020     2,881,065     $ 144,100     $ 8,745,700     $ 2,145,600       19,802     $ 52,400     $ 10,983,000                                                                           Additional                 Total       Common Stock     Paid-in     Retained     Treasury Stock     Shareholders’   Fiscal Year 2020:   Shares     Amount     Capital     Earnings     Shares     Amount     Equity                                               Balance, July 1, 2019     1,513,914     $ 75,700     $ 2,592,700     $ 3,724,700       19,802     $ 52,400     $ 6,340,700                                                             Net loss     -       -       -       (56,200 )     -       -       (56,200 )                                                           Stock options exercised     2,000       100       6,900       -       -       -       7,000                                                             Stock-based compensation     -       -       17,700       -       -       -       17,700                                                             Balance, September 30, 2019     1,515,914       75,800       2,617,300       3,668,500       19,802       52,400       6,309,200                                                             Net income     -       -       -       3,600       -       -       3,600                                                             Stock options exercised     6,661       300       (300 )     -       -       -       -                                                             Stock-based compensation     -       -       17,700       -       -       -       17,700                                                             Balance, December 31, 2019     1,522,575     $ 76,100     $ 2,634,700     $ 3,672,100       19,802     $ 52,400     $ 6,330,500                                                                          4     SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)       For the Six Month Period Ended December 31,     For the Six Month Period Ended December 31,       2020     2019   Operating activities:             Net loss   $ (875,800 )   $ (52,600 )        Adjustments to reconcile net loss used in operating activities:                             Gain (loss) on sale of investments     (33,300 )     (3,100 )             Unrealized holding gain (loss) on investments     25,700       (1,200 )             Depreciation and amortization     83,000       82,400               Deferred income taxes     (274,000 )     (20,100 )             Loss on disposal of subsidiary     405,400       -               Stock-based compensation     137,400       35,400               Changes in operating assets and liabilities:     -        -    Trade accounts receivable     (490,500 )     161,700   Inventories            (53,500 )     (411,500)   Right - of- use assets     38,200       (930,700 ) Income tax receivable     1,200       -   Prepaid and other current assets     (205,600 )     27,400   Lease liabilities     (28,400 )     998,100   Accounts payable     266,900       (94,300 ) Contract liabilities     (20,000 )     104,000   Bank overdraft     181,900       -   Accrued expenses and taxes     (376,400 )     (409,600 )                   Total adjustments     (342,000 )     (461,500 )                   Net used in operating activities     (1,217,800 )     (514,100 )                   Investing activities:                        Redemption of investment securities     544,800       51,900   Purchase of investment securities     (5,990,200 )     (61,800 ) Proceeds from sale of discontinued operations     342,400       -   Capital expenditures     (82,900 )     (34,100 ) Purchase of other intangible assets     (31,300 )     (7,400 )                   Net cash used in investing activities     (5,217,200 )     (51,400 )                   Financing activities:                        Payments of contingent consideration     (13,400 )     -          Proceeds from stock options exercised     -       7,000                     Net cash provided by (used in) financing activities     (13,400       7,000                     Net decrease in cash and cash equivalents     (6,448,400 )     (558,500 )                   Cash and cash equivalents, beginning of year     7,559,700       1,602,500                     Cash and cash equivalents, end of period   $ 1,111,300     $ 1,044,000                     Supplemental disclosures:                                   Cash paid during the period for:                 Income taxes   $ 2,500     $ 37,900                     Non-cash financing activities:                 Issuance of 6,661 shares of the Company's Common Stock in cashless stock option exercises during the three and six months ended December 31, 2019.                   See notes to unaudited condensed consolidated financial statements.    5       General:   The accompanying unaudited interim condensed consolidated financial statements are prepared pursuant to the Securities and Exchange Commission’s rules and regulations for reporting on Form 10-Q. Accordingly, certain information and footnotes required by accounting principles generally accepted in the United States for complete financial statements are not included herein. The Company believes all adjustments necessary for a fair presentation of these interim statements have been included and that they are of a normal and recurring nature. These interim statements should be read in conjunction with the Company’s financial statements and notes thereto, included in its Annual Report on Form 10-K, for the fiscal year ended June 30, 2020. The results for the three and six months ended December 31, 2020, are not necessarily an indication of the results for the full fiscal year ending June 30, 2021.   1. Summary of Significant Accounting Policies   Principles of Consolidation   The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Scientific Bioprocessing, Inc. (“SBI”) a Delaware corporation and wholly-owned subsidiary, and Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary, and Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary (all collectively referred to as the “Company”). All material intercompany balances and transactions have been eliminated.   COVID-19 Pandemic   The challenges posed by the COVID-19 pandemic on the global economy began to impact the Company’s operations at the end of the third quarter of the year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action as it pertains to COVID-19 preparedness by implementing the Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self -quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. However, if an employee becomes infected in the future, and the Company is forced to shut down for a period of time, it could have a short-term negative impact on operations. At the beginning of the pandemic, the Catalyst Research Instruments and Bioprocessing Systems Operations were shut down due to state mandates, however, the impact on operations was immaterial, and the Company was able to retain its employees without furloughs or layoffs, in part, due to the Company’s receipt of a $563,800 loan under the Federal Government’s Paycheck Protection Program. The Company did not experience and does not anticipate any material impact on its ability to collect its accounts receivable due to the nature of its customers, which are primarily distributors of laboratory equipment and supplies that have the ability to pay. However, there were some delays in receiving some accounts receivable due for catalyst research instruments due to customer shutdowns, and there was a material negative impact on the revenues of the Catalyst Research Instruments operations. The Company has not experienced and does not anticipate any material impairment to its tangible and intangible assets, system of internal controls, supply chain, or delivery and distribution of its products as a result of COVID-19, however the ultimate impact of COVID-19 on the Company’s business, results of operations, financial condition and cash flows is dependent on future developments, including the duration or worsening of the pandemic and the related length of its impact on the global economy, which are uncertain and cannot be predicted at this time.   Adopted Accounting Pronouncements   In August 2018, the Financial Standards Board (“FASB”) issued Accounting Standards Update ("ASU") 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement", which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard was effective for fiscal years beginning after December 15, 2019. Early adoption was permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements, with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented. The adoption of this standard on July 1, 2020 did not have a material impact on the Company’s financial statements.   Recent Accounting Pronouncements   In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years; this ASU allows for early adoption in any interim period after issuance of the update. The Company is currently evaluating the impact of adopting this guidance .    2. Revenue   The Company records revenues in accordance with Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, as amended” (“ASC Topic 606”). In accordance with ASC Topic 606, the Company accounts for a customer contract when both parties have approved the contract and are committed to perform their respective obligations, each party’s rights can be identified, payment terms can be identified, the contract has commercial substance, and it is probable that the Company will collect substantially all of the consideration to which it is entitled. Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer.      6       Nature of Products and Services   We generate revenues from the following sources: (1) Benchtop Laboratory Equipment, (2) Royalties, and (3) prior to November 30, 2020 Catalyst Research Instruments.   The following table summarizes the Company’s disaggregation of revenues for the three and six months ended December 31, 2020 and 2019.       Benchtop Laboratory Equipment     Bioprocessing Systems     Consolidated   Three Months Ended December 31, 2020:                                       Revenues   $ 2,507,400     $ 210,000     $ 2,717,400                             Foreign Sales     1,150,700       206,100       1,356,800         Benchtop Laboratory Equipment     Bioprocessing Systems     Consolidated   Three Months Ended December 31, 2019:                                       Revenues   $ 1,943,400     $ 289,400     $ 2,232,800                             Foreign Sales     855,800       289,400       1,145,200           Benchtop Laboratory Equipment     Bioprocessing Systems     Consolidated   Six Months Ended December 31, 2020:                                       Revenues   $ 4,437,600     $ 298,900     $ 4,736,500                             Foreign Sales     1,782,600       292,400       2,075,000         Benchtop Laboratory Equipment     Bioprocessing Systems     Consolidated   Six Months Ended December 31, 2019:                                       Revenues   $ 3,519,600     $ 578,700     $ 4,098,300                             Foreign Sales     1,253,400       578,700       1,832,100       Benchtop Laboratory Equipment sales are comprised primarily of standard benchtop laboratory equipment from its stock to laboratory equipment distributors, or to end users primarily via e-commerce. The sales cycle from time of receipt of order to shipment is very short varying from a day to a few weeks. Customers either pay by credit card (online sales) or net 30-90, depending on the customer. Once the item is shipped under the FOB terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. The standard warranty is typically comprised of one to two years of parts and labor and is deemed immaterial.   Royalty revenues pertain to royalties earned by the Company, which are paid on a calendar year basis, under a licensing agreement from a single licensee and its sublicenses. The Company is then obligated to pay 50% of all royalties received to the entity that licenses the intellectual property to the Company. During the year, the Company’s management uses its best judgement to estimate the royalty revenues earned during the period.   During the three months ended December 31, 2020, the Company discontinued its Catalyst Research Instruments Operations through the sale of substantially all of its assets on November 30, 2020. Refer to Note 9 for additional information.     7       The Company determines revenue recognition through the following steps:     ● Identification of the contract, or contracts, with a customer   ● Identification of the performance obligations in the contract   ● Determination of the transaction price   ● Allocation of the transaction price to the performance obligations in the contract   ● Recognition of revenue when, or as, a performance obligation is satisfied   The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC Topic 606: 1) all revenues are recorded net of returns, allowances, customer discounts, and incentives; 2) although sales and other taxes are immaterial, the Company accounts for amounts collected from customers for sales and other taxes, if any, net of related amounts remitted to tax authorities; 3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; 4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs fall within selling expenses; 5) the Company is always considered the principal and never an agent, because it has full control and responsibility until title is transferred to the customer; 6) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer such as is the case with catalyst instruments.     3. Segment Information and Concentrations   The Company views its operations as three segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”), the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical and petrochemical companies sold on a direct basis (“Catalyst Research Instruments Operations”) and the design and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing Systems Operations”).   Segment information is reported as follows:       Benchtop Laboratory Equipment     Bioprocessing Systems     Corporate And Other     Consolidated   Three Months Ended December 31, 2020:                                                   Revenues   $ 2,507,400     $ 210,000     $ -     $ 2,717,400                                     Foreign Sales     1,150,700       206,100       -       1,356,800                                     Income (Loss) From Continuing Operations     568,500       (741,800 )     (66,100 )     (239,400 )                                   Assets     6,140,400       966,400       6,962,800       14,069,600                                     Long-Lived Asset Expenditures     13,700       13,800       -       27,500                                     Depreciation and Amortization     26,400       15,800       200       42,400     Approximately $366,900 included in Assets relates to discontinued operations, and $200 in depreciation and amortization relates to discontinued operations.     Benchtop Laboratory Equipment     Bioprocessing Systems     Corporate And Other     Consolidated   Three Months Ended December 31, 2019:                                                   Revenues   $ 1,943,400     $ 289,400     $ -     $ 2,232,800                                     Foreign Sales     855,800       289,400       -       1,145,200                                     Income (Loss) From Continuing Operations     179,400       (18,100 )     -       161,300                                     Assets     5,551,100       1,350,000       1,962,700       8,863,800                                     Long-Lived Asset Expenditures     14,100       2,900       -       17,000                                     Depreciation and Amortization     30,800       10,400       200       41,400      8        Approximately $733,500 included in Assets relates to discontinued operations, and $200 in depreciation and amortization relates to discontinued operations.   Approximately 52% and 50% of total benchtop laboratory equipment sales (48% and 43% of total revenues) for the three months ended December 31, 2020 and 2019, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.   Approximately 23% and 24% of total benchtop laboratory equipment sales (21% and 21% of total revenues) were derived from the Torbal Scales Division for the three months ended December 31, 2020 and 2019, respectively.   For the three months ended December 31, 2020 and 2019, respectively, three customers accounted for approximately 20% and 27% of net sales of the Benchtop Laboratory Equipment Operations (18% and 24% of the Company’s total revenues).       Benchtop Laboratory Equipment     Bioprocessing Systems     Corporate And Other     Consolidated   Six Months Ended December 31, 2020:                                                   Revenues   $ 4,437,600     $ 298,900     $ -     $ 4,736,500                                     Foreign Sales     1,782,600       292,400       -       2,075,000                                     Income (Loss) From Continuing Operations     952,400       (1,274,100 )     (118,300 )     (440,100 )                                   Assets     6,140,400       966,400       6,962,800       14,069,600                                     Long-Lived Asset Expenditures     35,500       78,700       -       114,200                                     Depreciation and Amortization     52,700       29,800       500       83,000     Approximately $366,900 included in Assets relates to discontinued operations, and $500 in depreciation and amortization relates to discontinued operations.       Benchtop Laboratory Equipment     Bioprocessing Systems     Corporate And Other     Consolidated   Six Months Ended December 31, 2019:                                                   Revenues   $ 3,519,600     $ 578,700     $ -     $ 4,098,300                                     Foreign Sales     1,253,400       578,700       -       1,832,100                                     Income (Loss) From Continuing Operations     192,300       (16,200 )     -       176,100                                     Assets     5,551,100       1,350,000       1,962,700       8,863,800                                     Long-Lived Asset Expenditures     21,900       19,600       -       41,500                                     Depreciation and Amortization     61,300       20,500       600       82,400     Approximately $733,500 included in Assets relates to discontinued operations, and $600 in depreciation and amortization relates to discontinued operations.   Approximately 50% and 43% total benchtop laboratory equipment sales (47% and 37% of total revenues) for the six months ended December 31, 2020 and 2019, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.   Approximately 25% and 28% of total benchtop laboratory equipment sales (23% and 24% of total revenues) were derived from the Torbal Scales Division for the six months ended December 31, 2020 and 2019, respectively. For the six months ended December 31, 2020 and 2019, three customers accounted for approximately 21% and 25% of net sales of the Benchtop Laboratory Equipment Operations (20% and 22% of the Company’s total revenues), respectively.    9       4. Fair Value of Financial Instruments   The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements do not include transaction costs.   The accounting guidance also expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are described below:   Level 1 - Inputs that are based upon unadjusted quoted prices for identical instruments traded in active markets.   Level 2 - Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly.   Level 3 - Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.   In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments. These calculations take into consideration the credit risk of both the Company and its counterparties. The Company has not changed its valuation techniques in measuring the fair value of any financial assets and liabilities during the period.   The fair value of the contingent consideration obligations are based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following tables.   The following tables set forth by level within the fair value hierarchy the Company’s financial assets that were accounted for at fair value on a recurring basis at December 31, 2020 and June 30, 2020 according to the valuation techniques the Company used to determine their fair values:             Fair Value Measurements Using Inputs Considered as       Fair Value at December 31, 2020     Level 1     Level 2     Level 3   Assets:                         Cash and cash equivalents   $ 1,111,300     $ 1,111,300     $ -     $ -   Investment securities     5,784,800       5,784,800       -       -                                     Total   $ 6,896,100     $ 6,896,100     $ -     $ -                                     Liabilities:                                                                   Contingent consideration   $ 344,600     $ -     $ -     $ 344,600                   Fair Value Measurements Using Inputs Considered as       Fair Value at June 30, 2020     Level 1     Level 2     Level 3   Assets:                         Cash and cash equivalents   $ 7,559,700     $ 7,559,700     $ -     $ -   Investment securities     331,800       331,800       -       -                                     Total   $ 7,891,500     $ 7,891,500     $ -     $ -                                     Liabilities:                                                                   Contingent consideration   $ 358,000     $ -     $ -     $ 358,000        10         Investments in marketable securities classified as available for sale by security type at December 31, 2020 and June 30, 2020 consisted of the following:     Cost     Fair Value     Unrealized Holding Gain (Loss)   At December 31, 2020:                   Equity securities   $ 102,300     $ 134,100     $ 31,800   Mutual and bond funds     5,621,300       5,650,700       29,400                                 $ 5,723,600     $ 5,784,800     $ 61,200           Cost     Fair Value     Unrealized Holding Gain (Loss)   At June 30, 2020:                   Equity securities   $ 77,600     $ 101,900     $ 24,300   Mutual and bond funds     250,300       229,900       (20,400 )                               $ 327,900     $ 331,800     $ 3,900     5. Inventories   Inventories are valued at the lower of cost (determined on a first-in, first-out basis) or net realizable value, and have been reduced by an allowance for excess and obsolete inventories. The estimate is based on managements review of inventories on hand compared to estimated future usage and sales. Cost of work-in-process and finished goods inventories include material, labor, and manufacturing overhead.       December 31, 2020     June 30,2020   Raw materials   $ 1,791,500     $ 1,726,400   Work-in-process     116,000       35,700   Finished goods     731,700       778,900                         $ 2,639,200     $ 2,541,000     6. Goodwill and Other Intangible Assets   Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the Company’s acquisitions. Goodwill amounted to $257,300 at December 31, 2020 and June 30, 2020, all of which is expected to be deductible for tax purposes.                    The components of other intangible assets are as follows:     Useful Lives   Cost     Accumulated Amortization     Net   At December 31, 2020:                     Technology, trademarks 5/10 yrs.   $ 364,700     $ 362,100     $ 2,600   Trade names 6 yrs.     140,000       140,000       -   Websites 5 yrs.     210,000       210,000       -   Customer relationships 9/10 yrs.     120,000       91,100       28,900   Sublicense agreements 10 yrs.     294,000       268,300       25,700   Non-compete agreements 5 yrs.     282,000       282,000       -   IPR&D 3 yrs.     110,000       110,000       -   Other intangible assets 5 yrs.     277,900       207,200       70,900                                 $ 1,798,600     $ 1,670,500     $ 128,100        11           Useful Lives   Cost     Accumulated Amortization     Net   At June 30, 2020:                     Technology, trademarks 5/10 yrs.   $ 364,700     $ 362,000     $ 2,700   Trade names 6 yrs.     140,000       140,000       -   Websites 5 yrs.     210,000       210,000       -   Customer relationships 9/10 yrs.     120,000       84,400       35,600   Sublicense agreements 10 yrs.     294,000       253,600       40,400   Non-compete agreements 5 yrs.     282,000       282,000       -   IPR&D 3 yrs.     110,000       110,000       -   Other intangible assets 5 yrs.     246,600       196,600       50,000                                 $ 1,767,300     $ 1,638,600     $ 128,700     Total amortization expense was $16,200 and $19,800 for the three months ended December 31, 2020 and 2019, respectively, and $32,000 and $39,300 for the six months ended December 31, 2020 and 2019, respectively. As of December 31, 2020, estimated future amortization expense related to intangible assets is $42,400 for the remainder of the fiscal year ending June 30, 2021, $32,900 for fiscal 2022, $21,300 for fiscal 2023, $16,000 for fiscal 2024 and $15,500 thereafter.   7. Earnings (Loss) Per Common Share   The Company presents the computation of earnings per share (“EPS”) on a basic and diluted basis. Basic EPS is computed by dividing net income or loss by the weighted average number of shares outstanding during the reported period. Diluted EPS is computed similarly to basic EPS, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential additional common shares that were dilutive had been issued. Common shares are excluded from the calculation if they are determined to be anti-dilutive. The following table sets forth the weighted average number of common shares outstanding for each period presented       For the Three Month Period Ended December 31,  2020     For the Three Month  Period Ended December 31, 2019     For the Six Month Period Ended December 31, 2020     For the Six Month Period Ended December 31,  2019                             Weighted average number of common shares outstanding     2,861,263       1,499,396       2,861,263       1,496,718   Effect of dilutive securities     -       58,330       -       -   Weighted average number of dilutive common shares outstanding     2,861,263       1,557,726       2,861,263       1,496,718                                     Basic and diluted earnings (loss) per common share                                                                   Continuing operations   $ (.05 )   $ .09     $ (.10 )   $ (.09 ) Discontinued operations   $ (.17 )   $ (.09 )   $ (.21 )   $ (.13 ) Consolidated operations   $ (.22 )   $ .00     $ (.31 )   $ (.04 )   Approximately 126,700 shares and 1,349,850 of the Company’s common stock issuable upon the exercise of options and warrants, respectively, were excluded from the calculation for the three and six months ended December 31, 2020, because the effect would be anti-dilutive due to the loss for the periods. Approximately, 51,629 shares of the Company’s common stock issuable upon the exercise of the outstanding options were excluded from the calculation for the six months ended December 31, 2020 because they were anti-dilutive.      12       8. Leases   The Company recognizes all long-term leases on its balance sheet as a liability for its lease obligation, measured at the present value of lease payments not yet paid, and a corresponding asset representing its right to use the underlying asset over the lease term.   The Company leases certain properties consisting principally of a facility in Bohemia, New York (headquarters) through January 2025, a facility in Pittsburgh, Pennsylvania for its Bioprocessing Systems Operations through May 2023, and a sales and administration office in Orangeburg, New York for its Torbal Division of the Benchtop Laboratory Equipment Operations through October 2022. The Company also had a lease for its Catalyst Research Instruments Operations which terminated in November 2020 and the facility was shut down at the end of December 2020 in connection with the sale of that business segment on November 30, 2020. There are no renewal options with any of the leases, no residual values or significant restrictions or covenants other than those customary in such arrangements, and no non-cash activities, Any rent escalations incorporated within the leases are included in the calculation of the future minimum lease payments, as further described below. All of the Company’s leases are deemed operating leases.   The Company determines whether an agreement contains a lease at inception based on the Company’s right to obtain substantially all of the economic benefits from the use of the identified asset and its right to direct the use of the identified asset. Lease liabilities represent the present value of future lease payments and the Right-Of-Use (“ROU”) assets represent the Company’s right to use the underlying assets for the respective lease terms. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The ROU asset is further adjusted to account for previously recorded lease expenses such as deferred rent and other lease liabilities. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate of 5.0% as the discount rate to calculate the present value of future lease payments, which was the interest rate that its bank would charge for a similar loan.   The Company elected not to recognize a ROU asset and a lease liability for leases with an initial term of twelve months or less. In addition to minimum lease payments, certain leases require payment of a proportionate share of real estate taxes and certain building operating expenses or payments based on an excess of a specified base. These variable lease costs are not included in the measurement of the ROU asset or lease liability due to unpredictability of the payment amount and are recorded as lease expenses in the period incurred. The Company’s lease agreements do not contain residual value guarantees.   The Company elected available practical expedients for existing or expired contracts of lessees wherein the Company is not required to reassess whether such contracts contain leases, the lease classification or the initial direct costs. The Company is not utilizing the practical expedient which allows the use of hindsight by lessees and lessors in determining the lease term and in assessing impairment of its ROU assets. The Company utilized the transition method allowing entities to only apply the new lease standard in the year of adoption.   As of December 31, 2020, the weighted-average remaining lease term for operating lease liabilities was approximately 3.1 years and the weighted-average discount rate was 5.0%. Total cash payments under these leases were $76,100 and $154,700 for the three and six month periods ended December 31, 2020 of which $78,800 and $157,500 were recorded as leases expense.   The Company’s approximate future minimum rental payments under all leases existing at December 31, 2020 through February 2025 are as follows:   Fiscal year ending June 30,   Amount   Remainder of 2021   $ 128,000   2022     260,300   2023     245,300   2024     195,900   2025     91,600             Total future minimum payments     921,100   Less: Imputed interest     81,800             Total Present Value of Operating Lease Liabilities     839,300               13       9. Discontinued Operations   Effective November 30, 2020, the Company, as part of its strategic shift to becoming a life sciences tool provider, sold its Catalyst Research Instruments Operations reporting segment through the sale by Altamira of substantially all of its assets, which comprised of fixed assets, and inventory to Beijing JWGB Sci. & Tech. Co. Ltd., a corporation formed under the laws of the People’s Republic of China (“JWGB”) for $440,000 payable in cash through January 2021, resulting in a $405,400 pre-tax loss. In order to preserve business continuity for the buyer. Altamira agreed to purchase certain components on behalf of JWGB for which JWGB will reimburse Altamira. At December 31, 2020, JWGB owed the Company $97,600 related to the sale, and $39,500 for component purchases made on its behalf, all of which have been subsequently remitted to the Company. The Company retained all its receivables and payables related to sales made prior to November 30, 2020, certain inventory related to two work-in-process orders which will be shipped by the end of the fiscal year ending June 30, 2021, product warranty and other miscellaneous liabilities related to certain employee benefits, and expenses related to the closure of the Altamira facility, which was substantially completed at the end of December 2020.   As a result of the disposal described above, the operating results of the former Catalyst Research Instruments Operations segment have been presented as discontinued operations in the balance sheets, the statements of operations, and the statements of cash flows, as detailed below.   . Assets:   December 31, 2020     June 30,2020   Inventories   $ -     $ 343,700   Property and equipment, net     -       1,400   Goodwill     -       447,900                     Discontinued operations   $ -     $ 793,000       Liabilities:   December 31, 2020     June 30,2020   Accounts payable   $ 37,600     $ 20,100   Accrued expenses and taxes     44,900       120,700   Contract liabilities     69,000       69,000   Operating lease liabilities, current portion     -       31,100                         $ 151,500     $ 240,900     ​   Three Months Ended     Six Months Ended     December 31, 2020     December 31, 2019     December 31, 2020     December 31, 2019       ​       ​       ​       ​     Revenues     $ 142,700     $ 39,500     $ 279,900     $ 178,200     Cost of goods sold       195,500       128,300       379,700       262,600     Gross profit       (52,800 )     (88,800 )     (99,800 )     (84,400 )   Selling, general and administrative expenses       181,300       81,600       269,600       176,300     Loss from operations       (234,100 )     (170,400 )     (369,400 )     (260,700 )   Loss on disposal       (405,400 )     —       (405,400 )     —     Loss before income tax benefit       (639,500 )     (170,400 )     (774,800 )     (260,700 )   Income tax benefit, all deferred       165,300       34,700       179,900       72,100     Net loss attributable to discontinued operations     $ (474,200 )   $ (135,700 )   $ (594,900 )   $ (188,600 )   In our Consolidated Statements of Cash Flows, the cash flows from discontinued operations are not separately classified. Cash (used) and provided by operating activities from discontinued operations for the six months ended December 31, 2020 and December 31, 2019 was ($335,000) and $182,300, respectively. Cash provided by investing activities from discontinued operations for the six months ended December 31, 2020 was $342,400 and none for December 31, 2019. There was no cash provided or used by the discontinued operations for financing activities for both the current and prior year periods      14       It e m 2. Management's Discussion and Analysis of Financial Condition and Results of Operations   Forward-Looking statements. Certain statements contained in this report are not based on historical facts, but are forward-looking statements that are based upon various assumptions about future conditions. Actual events in the future could differ materially from those described in the forward-looking information. Numerous unknown factors and future events could cause such differences, including but not limited to, product demand, market acceptance, success of marketing strategy, success of expansion efforts, impact of competition, adverse economic conditions, and other factors affecting the Company’s business that are beyond the Company’s control, which are discussed elsewhere in this report. Consequently, no forward-looking statement can be guaranteed. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Company’s financial statements and the related notes included elsewhere in this report.   Overview.   The Company reflected a loss from continuing operations before income tax benefit of $185,900 and $374,900 for the three and six months ended December 31, 2020 compared to income before income tax expense of $173,400 and $188,000 for the three and six months ended December 31, 2019, primarily due to increased operating expenses incurred by the Company’s Bioprocessing Systems Operations. The Bioprocessing Systems Operations continues to expand with increased personnel and expenditures for product development, sales and marketing activities. The Benchtop Laboratory Equipment Operations recorded record sales and profits, principally due to higher sales of its flagship product, the Vortex-Genie®.   As part of the Company’s shift to becoming a life sciences tool provider, the Company divested and sold substantially all the assets of the Catalyst Research Instruments Operations at an approximate $405,400 loss, which is reflected in the total loss from discontinued operations, of $639,500 and $774,800 for the three and six months ended December 31, 2020, compared to an operating loss, for the discontinued operations of $170,400 and $260,700 for the three and six months ended December 31, 2019.   Results of Operations   The Three Months Ended December 31, 2020 Compared With The Three Months Ended December 31, 2019   Net revenues for the three months ended December 31, 2020 increased $484,600 (21.7%) to $2,717,400 from $ 2,232,800 for the three months ended December 31, 2019, reflecting an increase of $564,000 in sales of benchtop laboratory equipment, partially offset by decreased earned royalties of $79,400 by the Bioprocessing Systems Operations. The benchtop laboratory equipment sales reflected $576,800 and $476,100 of Torbal brand product gross sales for the three months ended December 31, 2020 and 2019, respectively.   The overall gross profit percentage for the three months ended December 31, 2020 was 51.7% and 52.8% for the three months ended December 31, 2019. While the gross margin percentage was lower for the Bioprocessing Systems Operations, the gross profit margin percentage for the Benchtop Laboratory Equipment Operations was higher due to increased sales.   General and administrative expenses for the three months ended December 31, 2020 increased by $58,500 (12.2%) to $536,900 compared to $478,400 for the three months ended December 31, 2019, due to the expansion of the Scientific Bioprocessing Systems Operations.   Selling expenses for the three months ended December 31, 2020 increased $498,300 (177.6%) to $778,900 from $ 280,600 for the three months ended December 31, 2019, due to increased sales and marketing costs related to personnel, websites, market research, and advertising expenses incurred by the Bioprocessing Systems Operations.   Research and development expenses increased by $69,700 (26.8%) to $329,700 for the three months ended December 31, 2020 compared to $260,000 for the three months ended December 31, 2019, primarily due to the ramp up in product development activities by the Bioprocessing Systems Operations which included staffing, facilities, and materials.   Total other income, net was $53,500 for the three months ended December 31, 2020 compared to $12,100 for the three months ended December 31, 2019 due to increased interest and dividend income generated from investment securities.   The Company reflected an income tax benefit related to continuing operations of $47,600 for the three months ended December 31, 2020 compared to income tax expense from continuing operations of $34,100 for the three months ended December 31, 2019 due to the loss for the period.   The Company reflected a loss from discontinued operations of $639,500 for the three months ended December 31, 2020, compared to $170,400 for the three months ended December 31, 2019, due to the loss on disposal in the current year period.   The Company reflected an income tax benefit related to discontinued operations of $165,300 for the three months ended December 31, 2020 compared to $34,700 for the three months ended December 31, 2019 due to the increased loss during the current year period.   The net loss from discontinued operations was $474,200 for the three months ended December 31, 2020 compared to $135,700 for the three months ended December 31, 2019, primarily due to the loss on disposal during the current year period.   As a result of the foregoing, the Company recorded a net loss of $612,500 for the three months ended December 31, 2020 compared to net income of $3,600 for the three months ended December 31, 2019.      15       The Six Months Ended December 31, 2020 Compared With The Six Months Ended December 31, 2019   Net revenues for the six months ended December 31, 2020 increased $638,200 (15.5%) to $4,736,500 from $ 4,098,300 for the six months ended December 31, 2019, reflecting a $918,000 increase in net sales of benchtop laboratory equipment, and a decrease of $279,800 in earned royalties by the Bioprocessing Systems Operations. The Benchtop Laboratory Equipment sales reflected $1,094,500 of Torbal brand gross product sales for the six months ended December 31, 2020, compared to $ 998,500 in the six months ended December 31, 2019.   The overall gross profit percentage for the six months ended December 31, 2020 was 51.9% and 52.6% for the six months ended December 31, 2019. While the gross margin percentage was lower for the Bioprocessing Systems Operations, the gross profit margin percentage for the Benchtop Laboratory Equipment Operations was higher due to increased sales.   General and administrative expenses for the six months ended December 31, 2020 increased $35,700 (11.3%) to $1,056,000 from $948,400 for the six months ended December 31, 2019, due to staffing and other administrative costs incurred by the Bioprocessing Systems Operations.   Selling expenses for the six months ended December 31, 2020 increased $737,400 (137.7%) to $1,272,800 from $535,400 for the six months ended December 31, 2019, due to increased sales and marketing costs related to personnel, websites, market research, and advertising expenses by the Bioprocessing Systems Operations.   Research and development expenses increased by $77,600 (15.6%) to $574,000 for the six months ended December 31, 2020 compared to $496,400 for the six months ended December 31, 2019, primarily due to increased new product development activities by the Bioprocessing Systems Operations which included staffing, facilities, and materials.   Total other income (expense), net was $65,100 for the six months ended December 31, 2020 compared to $11,900 for the six months ended December 31, 2019 principally due to increased interest income from investments.   The Company reflected an income tax benefit related to continuing operations of ($94,100) for the three months ended December 31, 2020 compared to income tax expense from continuing operations of $52,200 for the three months ended December 31, 2019 due to the loss for the period.   The Company reflected a loss from discontinued operations of $774,800 for the six months ended December 31, 2020, compared to $260,700 for the six months ended December 31, 2019, due to the loss on disposal in the current year period.   The Company reflected an income tax benefit related to discontinued operations of $179,000 for the six months ended December 31, 2020 compared to $72,100 for the six months ended December 31, 2019 due to the increased loss during the current year period.   The net loss from discontinued operations was $594,900 for the six months ended December 31, 2020 compared to $188,600 for the six months ended December 31, 2019, primarily due to the loss on disposal during the current year period.   As a result of the foregoing, the Company recorded a net loss of $875,800 for the six months ended December 31, 2020 compared to $52,600 for the six months ended December 31, 2019.   Liquidity and Capital Resources. Cash and cash equivalents decreased by $6,448,400 to $1,111,300 as of December 31, 2020 from $7,559,700 as of June 30, 2020, primarily due to converting cash on-hand to short term liquid investment securities and the loss for the period.   Net cash used in operating activities was $1,217,800 for the six months ended December 31, 2020 compared to net cash used of $514,100 during the six months ended December 31, 2019, primarily due to the increased loss for the period. Net cash used in investing activities was $5,217,200 for the six months ended December 31, 2020 compared to $51,400 used during the six months ended December 31, 2019, principally due to net purchases of investments, and to a lesser extent new capital equipment purchases by the Bioprocessing Systems Operations during the current period, partially offset by the cash received from the sale of the subsidiary. Net cash used in financing activities was $13,400 for the six months ended December 31, 2020, all due to contingent consideration payments made during the current year period, compared to cash proceeds of $7,000 during the six months ended December 31, 2019 from exercises of stock options .   The Company's working capital decreased by $937,400 to $9,611,100 as of December 31, 2020 compared to $10,548,500, as of June 30, 2020 mainly due to the loss during the period   The Company has a Demand Line of Credit through December 2021 with First National Bank of Pennsylvania which provides for borrowings of up to $300,000 for regular working capital needs, bearing interest at prime, 3.25% currently. Advances on the line, are secured by a pledge of the Company’s assets including inventory, accounts, chattel paper, equipment and general intangibles of the Company. As of December 31, 2020, no borrowings were outstanding under such line.   Management believes that the Company will be able to meet its cash flow needs during the 12 months ending December 31, 2021 from its available financial resources including the lines of credit, its cash and investment securities, and operations.       16     I t em 4. Controls and Procedures     Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this report, based on an evaluation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), the Chief Executive and Chief Financial Officer of the Company has concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in its Exchange Act reports is recorded, processed, summarized and reported within the applicable time periods specified by the SEC's rules and forms. The Company also concluded that information required to be disclosed in such reports is accumulated and communicated to the Company's management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.   As a result of our adoption of the new leases standard (Topic 842), we implemented controls to ensure adequate review and assessment of contracts containing leases and calculations of assets and liabilities related to the Company's leases as well as required disclosures within the Company's financial statements to facilitate its adoption on July 1, 2019. There were no significant changes to our internal control over financial reporting due to the adoption of the new standard, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f) during the period covered by this Quarterly Report or in other factors that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.     17       PART II – OTHER INFORMATION   I tem 6. Exhibits and Reports on Form 8-K       Exhibit Number   Description       31.   Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.   Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002     Reports on Form 8-K:   Current Report filed on Form 8-K dated July 22, 2020 reporting under Items 1.01 and 5.2.   Current Report filed on Form 8-K dated August 13, 2020 reporting under Item 5.03.   Current Report filed on Form 8-K dated December 1, 2020 reporting under Items 1.01 and 2.01.       SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.           Date: February 22, 2021   SCIENTIFIC INDUSTRIES, INC. (Registrant)   /s/ Helena R. Santos     Helena R. Santos President, Chief Executive Officer, Treasurer Chief Financial and Principal Accounting Officer                   18